Page last updated: 2024-11-04

pentagastrin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Pentagastrin: A synthetic pentapeptide that has effects like gastrin when given parenterally. It stimulates the secretion of gastric acid, pepsin, and intrinsic factor, and has been used as a diagnostic aid. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9853654
CHEMBL ID1328
CHEBI ID31974
SCHEMBL ID26045
MeSH IDM0016168

Synonyms (81)

Synonym
hsdb 3247
n-(alpha-carbamoylphenethyl)-3-(2-(2-(3-(carboxyamino)propionamido)-3-indol-3-ylpropionamido)-4-(methylthio)butyramido)succinamic acid n-tert-butyl ester
gastrodiagnost
pentagastrinum [inn-latin]
n-(n-(n-(n-(n-tert-butoxycarbonyl-beta-alanyl)-l-tryptophanyl)-l-methionyl)-l-aspartyl)-l-phenylalaninamide
ay 6608
boc-beta-ala-try-met-asp-phe(nh2)
brn 5472892
ici 50123
pentagastrin [usan:inn:ban:jan]
petogasrin
nsc 367746
alaninamide, n-carboxy-beta-alanyl-l-tryptophyl-l-methionyl-l-aspartylphenyl-, n-tert-butylester, l-
einecs 226-889-7
n-t-butyloxycarbonyl-beta-alanyl-l-tryptophyl-l-methion yl-l-aspartyl-l-phenylalanine amide
l-phenylalaninamide, n-((1,1-dimethylethoxy)carbonyl)-beta-alanyl-l-tryptophyl-l-methionyl-l-alpha-aspartyl-
alaninamide, n-carboxy-beta-alanyl-l-tryptophyl-l-methionyl-l-aspartylphenyl-, n-tert-butyl ester, l-
peptavlon
pentagastrina [inn-spanish]
n-carboxy-beta-alanyl-l-tryptophyl-l-methionyl-l-aspartylphenyl-l-alaninamide n-tert-butyl ester
pentagastrine [inn-french]
nsc-367746
pentagastrin
DB00183
peptavlon (tn)
pentagastrin (jan/usan/inn)
D01631
NCGC00167300-01
pentapeptide, gastrin
gastrin pentapeptide
CHEMBL1328 ,
ici 50,123
ay-6608
ici-50123
3-{2-[2-(3-tert-butoxycarbonylamino-propionylamino)-3-(1h-indol-3-yl)-propionylamino]-4-methylsulfanyl-butyrylamino}-n-(1-carbamoyl-2-phenyl-ethyl)-succinamic acid
bdbm50024321
NCGC00183362-01
tox21_113479
cas-5534-95-2
dtxsid3048992 ,
dtxcid9028918
ef0nx91490 ,
pentagastrina
pentagastrinum
pentagastrine
unii-ef0nx91490
MLS006009992
smr004701067
SCHEMBL26045
NCGC00183362-02
tox21_113479_1
pentagastrin [usan]
pentagastrin [vandf]
pentagastrin [jan]
pentagastrin [inn]
n-carboxy-.beta.-alanyl-l-tryptophyl-l-methionyl-l-aspartylphenyl-l-alaninamide n-tert-butyl ester
pentagastrin [hsdb]
pentagastrin [mi]
l-phenylalaninamide, n-((1,1-dimethylethoxy)carbonyl)-.beta.-alanyl-l-tryptophyl-l-methionyl-l-.alpha.-aspartyl-
pentagastrin [who-dd]
pentagastrin [mart.]
pentagastrin [orange book]
mfcd00076515
AKOS030213248
CS-5667
HY-A0261
CHEBI:31974
Q423586
boc-beta-ala-trp-met-asp-phe-nh2
(10s,13s,16s)-10-((1h-indol-3-yl)methyl)-16-((s)-1-amino-1-oxo-3-phenylpropan-2-ylcarbamoyl)-2,2-dimethyl-13-(2-(methylthio)ethyl)-4,8,11,14-tetraoxo-3-oxa-5,9,12,15-tetraazaoctadecan-18-oic acid
EX-A7390
AS-56396
(3s)-3-[(2s)-2-[(2s)-2-(3-{[(tert-butoxy)carbonyl]amino}propanamido)-3-(1h-indol-3-yl)propanamido]-4-(methylsulfanyl)butanamido]-3-{[(1s)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic acid
EN300-19736421
pentagastrin (mart.)
pentagastrine (inn-french)
n-(alpha-carbamoylphenethyl)-3-
v04cg04
petavlon
pentagastrina (inn-spanish)
pentagastrinum (inn-latin)

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Warmth feeling was the most frequent occurring side effect in all patients who had both pentagastrin and calcium stimulation tests, followed by nausea, altered gustatory sensation, and dizziness."( Comparison of side effects of pentagastrin test and calcium stimulation test in patients with increased basal calcitonin concentration: the gender-specific differences.
Crevenna, R; Gincu, T; Hacker, M; Keilani, M; Li, S; Niederle, B; Ponhold, L; Ubl, P, 2014
)
0.4

Pharmacokinetics

ExcerptReferenceRelevance
" The increase in potency appears to be related in part to a decrease in the metabolic clearance rate in vivo (6-fold) and, in vitro, to an increase in half-life (3-fold) when incubated with rat liver plasma membranes."( N-acetyl oxyntomodulin30-37: pharmacokinetics and activity on gastric acid secretion.
Bataille, D; Carles-Bonnet, C; Jarrousse, C; Martinez, J; Niel, H; Rolland, M, 1992
)
0.28
" A good dose linearity was observed for AUC (0, infinity) and Cmax over the dose range from 5 to 80 mg."( Single intravenous administration of the H+, K(+)-ATPase inhibitor BY 1023/SK&F 96022--inhibition of pentagastrin-stimulated gastric acid secretion and pharmacokinetics in man.
Bliesath, H; Hartmann, M; Huber, R; Lühmann, R; Müller, P; Simon, B; Wurst, W, 1990
)
0.28
" AUC, Cmax and t1/2 of the drug after repeated oral intake were not significantly different when compared with a single dose at either 20 mg or 40 mg."( Effect of repeated oral administration of BY 1023/SK&F 96022--a new substituted benzimidazole derivative--on pentagastrin-stimulated gastric acid secretion and pharmacokinetics in man.
Hartmann, R; Huber, R; Lühmann, R; Marinis, E; Müller, P; Simon, B; Wurst, W, 1990
)
0.28
" Repeated once-daily infusion (15 min) of pantoprazole resulted in a rapidly increasing pharmacodynamic effect: as compared to placebo the mean percent inhibition of acid output measured from 1 to 3 h after start of infusion was 22%, 63% and 78% for the 15 mg dose, and 56%, 97% and 99% for the 30 mg dose on days 1, 4 and 5, respectively."( Pentagastrin-stimulated gastric acid secretion and pharmacokinetics following single and repeated intravenous administration of the gastric H+, K(+)-ATPase-inhibitor pantoprazole (BY1023/SK&F96022) in healthy volunteers.
Bliesath, H; Bohnenkamp, W; Hartmann, M; Huber, R; Lühmann, R; Müller, P; Simon, B; Wurst, W, 1990
)
0.28
"7 ml kg-1 min-1 and the half-life in plasma was 12 +/- 1 min."( Oxyntomodulin: a potential hormone from the distal gut. Pharmacokinetics and effects on gastric acid and insulin secretion in man.
Baldissera, FG; Christiansen, J; Holst, JJ; Mortensen, PE; Schjoldager, BT, 1988
)
0.27
"A sensitive and specific high pressure liquid chromatographic procedure for ranitidine estimation is described and pharmacokinetic studies in six healthy volunteers reported."( Pharmacokinetic and gastric secretory studies of ranitidine in man.
Anderson, A; Hanson, RG; Louis, WJ; McNeil, JJ; Mihaly, GW; Smallwood, RA; Yeomans, ND, 1981
)
0.26
" In non-ascitic cirrhotic patients, pharmacokinetic parameters are similar to those published in healthy subjects."( [Pharmacokinetics of intravenous ranitidine and its effect on gastric acid secretion stimulated by pentagastrin in the cirrhotic].
Allain, H; Bretagne, JF; Gastard, J; Gosselin, A; Reymann, JM; Tassou, JJ, 1983
)
0.27
"05, respectively) after MD than after SD, but the half-life (t1/2) and minimum concentration (Cmin) 12 h postdosing did not differ."( The pharmacokinetics of ranitidine in patients with chronic duodenal ulceration: a comparison of responders and non-responders.
Folb, PI; Marks, IN; McFadyen, ML; Miller, R; Moshal, MG, 1983
)
0.27
"04 micrograms/ml), the area under the plasma concentration curve (A."( Pharmacokinetics of cimetidine in patients with unresponsive duodenal ulcer.
Alfieri, G; Benvenuti, C; Foschi, D; Rovati, V, 1983
)
0.27

Compound-Compound Interactions

ExcerptReferenceRelevance
"5, and 15 mug/kg/hr, either alone or in combination with carbacholine, 2 mug/kg/hr."( Gastric secretory response to graded doses of pentagastrin alone or in combination with carbacholine in unoperated duodenal ulcer patients.
Roland, M, 1975
)
0.25

Bioavailability

ExcerptReferenceRelevance
" 3 Cimetidine was well absorbed by mouth and had a blood half-life of 2 hours."( Pharmacological evaluation of cimetidine, a new histamine H2-receptor antagonist, in healthy man.
Burland, WL; Duncan, WA; Haggie, SJ; Hesselbo, T; Mills, JG; Sharpe, PC; Wyllie, JH, 1975
)
0.25
" Ranitidine pretreatment reduced enoxacin oral bioavailability by an average of 26%."( Effect of gastric acidity on enoxacin absorption.
Lebsack, ME; Nix, D; Norman, AM; Ryerson, B; Schentag, JJ; Sedman, AJ; Toothaker, RD; Welage, L, 1992
)
0.28
" Omeprazole, and presumably other gastric-acid inhibitors, may increase the bioavailability of unchanged digoxin."( Influence of gastric acidity on the bioavailability of digoxin.
Cohen, AF; Hoogkamer, H; Kroon, R; Schoemaker, R; van Vliet, A, 1991
)
0.28
" The estimated elimination half-life was 140 minutes and the bioavailability of the oral drug was about 50%."( Ranitidine--a new H2-receptor antagonist.
Carey, P; Dixon, GT; Harrison, C; Richards, DA; Woodings, EP, 1980
)
0.26
" Bioavailability was unaffected by food and AUC increased linearly with dose to 100 mg."( Pharmacokinetic and gastric secretory studies of ranitidine in man.
Anderson, A; Hanson, RG; Louis, WJ; McNeil, JJ; Mihaly, GW; Smallwood, RA; Yeomans, ND, 1981
)
0.26
" The oral bioavailability of ranitidine in these 5 patients showed wide variation (27-76%; mean 51%)."( The pharmacokinetics of ranitidine in patients with chronic duodenal ulceration: a comparison of responders and non-responders.
Folb, PI; Marks, IN; McFadyen, ML; Miller, R; Moshal, MG, 1983
)
0.27
" Rectal bioavailability was quantitated by direct comparison of pharmacological effect with intravenous dose response."( Enhanced rectal bioavailability of polypeptides using sodium 5-methoxysalicylate as an absorption promoter.
Caldwell, L; Higuchi, T; Yoshioka, S, 1982
)
0.26
" 2 The compound which is moderately well absorbed after oral ingestion, was taken for 5 days prior to the measurement of acid secretion and was also given intravenously during part of the gastric test."( Inhibition of gastric acid secretion with a mast cell stabiliser, FPL-52694.
Davies, HA; Rhodes, J; Thomas, M, 1981
)
0.26
" Oral absorption of didanosine was rapid and complete; but due to first pass metabolism, the absolute bioavailability of didanosine was 44%."( Absorption, disposition, and metabolism of [14C]didanosine in the beagle dog.
Barbhaiya, RH; Dandekar, KA; Kaul, S; Shukla, UA; Shyu, WC,
)
0.13
" The superiority of the GI physiology regulated-dogs over the intact dogs was confirmed by comparative bioavailability studies using two classes of preparations of poorly water-soluble 4-(2-chlorophenyl)-2-[2-(4-isobutylphenyl)ethyl]-6,9-dimethyl-6H- thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine (Y-24180)."( Gastrointestinal physiology-regulated dogs: utilization of a bioavailability study of a new thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]-diazepine, an antagonist of platelet-activating factor, and its preparations.
Kawazoe, Y; Mizuta, H; Sagara, K; Shibata, M; Yamada, I, 1994
)
0.29
" Since the rate of absorption is also strongly influenced by the rapidity of gastric emptying, we have compared the relative importance of gastric acidity and gastric emptying in overall F absorption."( Influence of gastric acidity on fluoride absorption in rats.
Messer, HH; Ophaug, RH, 1993
)
0.29
" The absolute bioavailability of didanosine from a saline solution decreased from approximately 43% in untreated dogs to 8% after pretreatment with pentagastrin."( Biopharmaceutics of didanosine in humans and in a model for acid-labile drugs, the pentagastrin-pretreated dog.
Barbhaiya, RH; Knupp, CA; Lee, JS; Morgenthien, EA; Shyu, WC, 1993
)
0.29
" In contrast, the bioavailability of C-granule was only 35% in the intact dogs, but was 55% in the regulated dogs."( Gastrointestinal physiology-regulated dogs for bioavailability evaluation of an oral controlled-release dosage form composed of pulsatile release granules.
Kawata, M; Matsuura, Y; Sagara, K; Shibata, M; Yamada, I, 1996
)
0.29
" (3R)-N-[1-[(tert-butylcarbonyl)methyl]-2,3-dihydro-2-oxo-5-(2-pyri dyl) -1H-1,4-benzodiazepin-3-yl]-N'-[3-(methylamino)phenyl]urea, 15c (YF476), and (3R)-N-[1-[(tert-Butylcarbonyl)methyl]-2,3-dihydro-2-oxo-5- (2-pyridyl)-1H-1,4-benzodiazepin-3-yl]-N'-[3-(dimethylamino)phenyl ]urea hydrochloride, 15d, showed potent dose-dependent effects in both models with the former showing excellent oral bioavailability and an ED50 of 21nmol/kg po in dogs."( (3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl)-N'-(3-(methylamino)phenyl)urea (YF476): a potent and orally active gastrin/CCK-B antagonist.
Akuzawa, S; Batt, AR; Kendrick, DA; Miyata, K; Nishida, A; Ohta, M; Rooker, DP; Ryder, H; Satoh, M; Semple, G; Szelke, M, 1997
)
0.3
"The effect of formulation on oral bioavailability of the antiviral nucleotide analogue adefovir from the prodrug adefovir dipivoxil was examined in beagle dogs."( Oral formulations of adefovir dipivoxil: in vitro dissolution and in vivo bioavailability in dogs.
Cundy, KC; Lee, WA; Marshburn, J; Nakamura, C; Shaw, JP; Sue, IL; Visor, GC, 1997
)
0.3
" In conclusion, in vivo models using rats and dogs were optimized to evaluate the effects of gastric acid on the oral bioavailability of drugs, and demonstrated that in vivo models can lead to a better understanding of the oral bioavailability, with respect to the formulation development."( Evaluation of Acid Tolerance of Drugs Using Rats and Dogs Controlled for Gastric Acid Secretion.
Amano, N; Fujioka, Y; Furuta, A; Igari, T; Kosugi, Y; Sano, N; Yamamoto, S, 2015
)
0.42

Dosage Studied

The acid response to pentagastrin 1-16 microgram kg-1 hr-1 assayed on a single occasion by a continuous infusion method. During dosing with omeprazole, basal gastric acid output diminished by 94%. The effect of a specific histamine H2-receptor antagonist, metiamide, on the acid dose-response curves for penta.

ExcerptRelevanceReference
" A linear dose-response relationship was obtained for theophylline."( Acid secretion by guinea-pig isolated stomach.
Holton, P; Spencer, J, 1976
)
0.26
"v botulinum toxin after 60-90 min abolished the dose-response relationship between pentagastrin and gastric acid secretion in anesthetized rats and guinea-pigs."( Modification of the action of pentagastrin on acid secretion by botulinum toxin.
Kondo, T; Magee, DF, 1977
)
0.26
"For the definition of histamine receptors the following prerequisites must be fulfilled: (1) Course of dose-response curves according to the mass-action law; (2) parallel displacement of these curves to the right in the presence of antagonists; (3) inhibition only by specific histamine antagonists; (4) slope of a Schild-plot not significantly different from unity."( [Histamine and its role in peptic gastric diseases: the discovery of histamine-H2-receptor antagonists].
Barth, H; Lorenz, W, 1978
)
0.26
" Evaluation of dose-response relationships showed that in duodenal ulcer patients the secretion of gastric lipase and pepsin is more sensitive to pentagastrin stimulation than that of hydrogen ions."( Coupled secretion of gastric lipase and pepsin in man following pentagastrin stimulation.
Popiela, T; Szafran, H; Szafran, Z; Trompeter, G, 1978
)
0.26
" Drug dosage and time after the drug effect was measured varied."( [Comparative study on the effect of anticholinergic substances on basic gastric secretion as well as on gastric secretion stimulated by pentagastrin or hypoglycemia (author's transl)].
Brenner, U; Kutz, K; Miederer, SE; Schuler, G, 1976
)
0.26
" Intravenous pentagastrin in a dose of 0,5 mug per kg could thus achieve the same extent of discrimination between individuals with a 10-fold economy in dosage over subcutaneous pentagastrin."( Intravenous pentagastrin as a partial agonist of gastric secretion in man: evidence in favor of the existence of hormonal inhibitory sites.
Makhlouf, GM; Prugh, MF; Schorr, BA; Vlahcevic, ZR, 1975
)
0.25
" The effect of a specific histamine H2-receptor antagonist, metiamide, on the acid dose-response curves for pentagastrin or methacholine was studied in rats provided with Heidenhain pouches."( Displacement by metiamide of the dose-response curves to pentagastrin and methacholine in the conscious rat.
Lundell, L, 1975
)
0.25
"The effects of atropine on pentagastrin-stimulated gastric secretion of water, H, Cl, Na, K, and pepsin were determined by kinetic analysis of dose-response studies in 5 dogs with esophagostomy and gastric cannula."( Kinetics of atropine inhibition of pentagastrin-stimulated H+, electrolyte, and pepsin secretion in the dog.
Hirschowitz, BI; Hutchison, GA, 1977
)
0.26
" Analysis of dose-response curves shows that for pepsin secretion the Vmax values were raised by this procedure."( The secretion of pepsin.
Kondo, T; Magee, DF, 1977
)
0.26
" In another group of seven dogs with a gastric fistula, dose-response curves to pnetagastrin (PPG, 0 to 5 microgram/kg/hr) were determined."( Gastric acid secretion after chemical sympathectomy.
Ahlman, BH; Bombeck, CT; Larson, GM; Nyhus, LM, 1979
)
0.26
"The secretion of HCl and sialic acid into the gastric juice was investigated in 13 patients with gastric, 52 with duodenal ulcers and 27 control patients, during the dose-response pentagastrin test."( Sialic acid secretion of patients with gastric and duodenal ulcers in the dose-response pentastrin test.
Ahola, T; Ala-Kaila, K; Keyriläinen, O; Uusitalo, A, 1979
)
0.26
" Dose-response experiments with 6 doses of pentagastrin and 1 dose of salmefamol showed a decrease in calculated maximal response (CMR) and an unchanged D50."( Inhibition of gastric acid secretion in dogs by a new sympathomimetic drug.
Gottrup, F; Ornsholt, J, 1978
)
0.26
"Time-response and dose-response curves for acid output to continuous infusion of histamine (HIST) and pentagastrin (PG) were determined by two techniques in conscious rats provided with chronic gastric fistula."( Comparison of the step-dose and single-dose acid response to histamine and pentagastrin in chronic gastric fistula rats.
Genton, MJ; Pascaud, XB; Roger, AR, 1977
)
0.26
" The dose-response curves for these three effects of bombesin were very similar, with effects being detectable at concentrations of about 30 pM and maximal effects at about 10 nM."( In vitro action of bombesin on amylase secretion, membrane potential, and membrane resistance in rat and mouse pancreatic acinar cells. A comparison with other secretagogues.
Iwatsuki, N; Petersen, OH, 1978
)
0.26
" An intravenous dose-response curve with increasing doses of pentagastrin resulted in 30% higher MAO compared to subcutaneously administered pentagastrin (6 microgram/kg body weight)."( [Progress in diagnosis of gastric function: gastric secretory analysis, intragastric titration, endocrine provocation tests (author's transl)].
Becker, HD, 1978
)
0.26
" The acid response to pentagastrin 1-16 microgram kg-1 hr-1 assayed on a single occasion by a continuous infusion method shows a dose-response relationship up to 8 microgram kg-1 hr-1 when it reaches a plateau of secretion."( Characteristics and tachyphylaxis of gastrin-stimulated gastric acid secretion in the cat.
Hirst, BH; Labib, LA; Reed, JD, 1978
)
0.26
" In a second study a similar difference was observed between IT and AT data throughout the whole range of the pentagastrin dose-response curve."( A comparison between intragastric titration and aspiration technique under basal conditions and after food or pentagastrin stimulation.
Halter, F; Keller, M, 1978
)
0.26
" Supra-maximal doses and repetition of the dose-response protocol gave smaller increments for body tone and antral force, while the increase in contractile frequency remained unaffected."( Motor effects of graded doses of pentagastrin on the gut of the anesthetized dog.
Beijer, HJ; Brouwer, FA; Charbon, GA; Schuurkes, JA, 1978
)
0.26
"3 These peptide secretagogues were divided into the gastrin group and the CCK-PZ group according to the time course of the depolarizations and the shape of the dose-response curve."( The effects of gastrin and gastrin analogues on pancreatic acinar cell membrane potential and resistance.
Iwatsuki, N; Kato, K; Nishiyama, A, 1977
)
0.26
" Intravenous infusion of histamine caused marked displacement of the pentagastrin dose-response curve, in a manner suggesting a reduced sensitivity to pentagastrin."( Suppression of rat stomach histidine decarboxylase activity by histamine: H2-receptor-mediated feed-back.
Håkanson, R; Larsson, LI; Liedberg, G; Rehfeld, JF; Sundler, F, 1977
)
0.26
" Increasing doses of extract stimulated increasing acid production according to a regular dose-response relationship."( Further evidence for an intestinal phase hormone that stimulates gastric acid secretion.
Charters, AC; Nakaji, NT; Orloff, MJ, 1976
)
0.26
" The responsiveness of the LES to intravenous pentagastrin was quantitatively reduced throughout the whole range of the dose-response curve in patients with ulcerative esophagitis, whereas patients with non-ulcerative esophagitis only differed in the maximum mbe pressure value from the controls."( Lower esophageal sphincter in reflux esophagitis.
Halter, F; Scheurer, U, 1976
)
0.26
" The study suggests that pentagastrin dose-response does not provide more diagnostic information than a single dose (1 mug/kg-hr), which is maximal for pepsin and submaximal for acid."( Pentagastrin dose-response in peptic ulcer disease.
Myren, J; Petersen, H, 1975
)
0.25
" Limited dose-response studies showed that 0-25 mug urogastrone kg--1 hr--1 resulted in inhibition of acid output of 80% and was not associated with clinical side-effects."( Effect of urogastrone on gastric secretion and plasma gastrin levels in normal subjects.
Elder, JB; Ganguli, PC; Gerring, EL; Gillespie, IE; Gregory, H, 1975
)
0.25
" Therefore, individual dose-response studies were performed in two normal subjects."( Effect of continuous infusion of pentagastrin on lower esophageal sphincter pressure and gastric acid secretion in normal subjects.
Fordtran, JS; Frank, SA; Manton, J; Walker, CO, 1975
)
0.25
" We conclude that glucagon at sufficient dosage has an inhibitory effect on LES pressure."( Effect of glucagon on esophageal motor function.
Arndorfer, RC; Dodds, WJ; Hogan, WJ; Hoke, SE; Kalkhoff, RK; Reid, DP, 1975
)
0.25
" On histamine-stimulated secretion, the differences between the acetylated and the free octapeptides were that the former displayed a dose-response curve parallel to that of oxyntomodulin and a 4-fold higher potency."( N-acetyl oxyntomodulin30-37: pharmacokinetics and activity on gastric acid secretion.
Bataille, D; Carles-Bonnet, C; Jarrousse, C; Martinez, J; Niel, H; Rolland, M, 1992
)
0.28
"In a double-blind study of Latin square design, twelve healthy male subjects were dosed with combinations of ranitidine 300 mg or placebo (at 08."( Intravenous pentagastrin can induce the illusion of 'tolerance' to a single dose of an H2-blocker in man.
Nwokolo, CU; Pounder, RE; Sawyerr, A; Smith, JT, 1990
)
0.28
" Use of the insert achieved an earlier steady secretory response which allowed cumulative dosing to be performed in each animal."( Use of a cannula insert in erratic emptying Heidenhain pouch dogs: effect of single and cumulative doses of omeprazole.
Ghelani, A; Radziwonik, H, 1990
)
0.28
" Dose-response tests estimated that the maximally effective intravenous dose of pentagastrin was between 3 and 6 micrograms."( Basal and pentagastrin-stimulated gastric secretion in young horses.
Campbell-Thompson, ML; Merritt, AM, 1990
)
0.28
" Dose-response curves for pentagastrin pulses show that both the total amount of histamine released and the total amount of acid secreted are saturable processes, paralleling each other."( Histamine: the sole mediator of pentagastrin-stimulated acid secretion.
Ekblad, EB, 1985
)
0.27
" The dose-response curve for carbachol was biphasic."( Stimulation of acid formation by histamine, carbachol and pentagastrin in isolated pig parietal cells.
Ljungström, M; Mårdh, S; Norberg, L; Vega, FV, 1986
)
0.27
" Seven days' dosing with 60 mg AG-1749 induced a more than threefold increment of fasting serum gastrin concentration, but this increase was still within the normal range."( Human gastric acid secretion following repeated doses of AG-1749.
Dammann, HG; Leucht, U; Müller, P; Simon, B, 1989
)
0.28
" During dosing with omeprazole, basal gastric acid output diminished by 94%, and pentagastrin-stimulated acid output by 97%."( Repeated high oral doses of omeprazole do not affect intrinsic factor secretion: proof of a selective mode of action.
Den Hollander, W; Festen, HP; Meuwissen, SG; Tuynman, HA, 1989
)
0.28
" Omeprazole caused a non-competitive inhibition of the dose-response curve to dimaprit, whereas famotidine induced a parallel shift to the right without depressing the maximum response."( Antisecretory activity of omeprazole in the conscious gastric fistula cat: comparison with famotidine.
Bertaccini, G; Coruzzi, G,
)
0.13
" In the pH study (n = 17 subjects), there was a lead-in period done under fasting conditions, followed by randomization to a four-way crossover of pentagastrin (6 micrograms/kg, subcutaneously), ranitidine (150 mg orally, 10 and 2 hours before dosing with the antibiotic), sodium bicarbonate (12."( The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil.
Barker, KB; Batts, DH; Euler, AR; Heald, DL; Hughes, GS; Patel, RK; Spillers, CR; Watts, KC, 1989
)
0.28
" Dose-response curves for methacholine-induced acid and pepsin secretion at the perigee did not differ from those obtained with ganglionic blockade."( A comparative study of gastric secretory stimulants in conscious dogs.
Magee, DF; Naruse, S; Pap, A, 1989
)
0.28
" Pentagastrin-stimulated acid secretion remained decreased (50% of control) 12 hr after oral dosing with 20 mg famotidine."( Famotidine, a new H2-receptor antagonist. Effect on parietal, nonparietal, and pepsin secretion in man.
Chremos, AN; Gamal, MA; Graham, DY; Smith, JL, 1985
)
0.27
"The effect of serotonin on pentagastrin-stimulated gastric pepsin secretion in dogs was evaluated with regard to dose-response kinetics and receptor mediation."( Effect of serotonin on pentagastrin-stimulated gastric pepsin secretion in dogs with gastric fistula.
Andersen, D; Bech, K, 1985
)
0.27
" Dose-response curves were determined for acid output and for mucosal blood flow, which was measured with the neutral red technique."( Acid secretion and mucosal blood flow in the distal and proximal parts of the canine parietal cell mass in response to cholinergic stimulation.
Larsson, JO, 1985
)
0.27
" The reaction patterns were similar for isoprenaline and somatostatin, whereas salmefamol induced an inhibition of longer duration and with dissimilar dose-response kinetics."( Beta-adrenergic agonists inhibit gastric acid and pepsin secretion through somatostatin release in dogs.
Bech, K; Uvnäs-Moberg, K, 1986
)
0.27
" Intravenous infusion of CM 57755 induced a parallel shift to the right of the dimaprit dose-response curve."( Inhibition of dimaprit- and pentagastrin-induced gastric acid secretion in cats by the new histamine H2 antagonist, CM 57755.
Bianchetti, A; Lavezzo, A; Manara, L; Manzoni, L, 1986
)
0.27
" Dose-response analysis showed inhibition of non-competitive types."( Effect of serotonin on pentagastrin-stimulated gastric acid secretion and gastric antral motility in dogs with gastric fistula.
Andersen, D; Bech, K, 1985
)
0.27
" There was a significant positive dose-response relationship between pentagastrin and acid and fistula pepsin secretions, but not between plasma gastrin of endogenous origin and gastric secretion."( The relationship between blood gastrin levels and gastric secretion in conscious dogs.
Magee, DF; Murphy, RF; Naruse, S, 1988
)
0.27
" These results showed that the ranitidine is a potent antisecretory drug; the dosage of 150 mg twice a day which is considered as the regular treatment for ulcer disease seems adequate."( [Ranitidine inhibition of gastric secretion stimulated by pentagastrin. Results in 30 cases of duodenal ulcer].
Bosc, F; Pagniez, R; Rousselet, J; Toulet, J; Vienne, JL; Viteau, JM,
)
0.13
"The tolerability of the compound AWD 26-06 (which is to classify as a M1-antagonist in consequence of the pharmacological investigations) was investigated in 11 healthy male persons with increasing dosage from 5 to 150 mg."( [Clinico-pharmacologic studies with a M1 receptor antagonist (substance AWD 26-06) in a phase I clinical trial].
Feller, K; Gramatté, T; Terhaag, B, 1988
)
0.27
"By means of a dose-response secretion test the sensitivity of gastric acid secretion was investigated in 85 patients with chronic renal failure and in 85 age- and sex-matched controls."( Sensitivity of gastric acid secretion in patients with chronic renal failure.
Ala-Kaila, K; Kataja, M; Keyriläinen, O; Pasternack, A; Sipponen, P, 1987
)
0.27
"A dose-response gastric secretion test was performed in 87 nondialyzed patients with chronic renal failure (CRF) and in 87 age- and sex-matched controls without renal disease."( Gastric secretion kinetics in chronic renal failure.
Ala-Kaila, K, 1987
)
0.27
" At each measured serum gastrin concentration after either exogenous G17 or intragastric peptone meals, cirrhotics with portacaval shunt secreted more acid than the unshunted control groups and their dose-response curve was significantly shifted to the left."( Increased sensitivity of gastric acid secretion to gastrin in cirrhotic patients with portacaval shunt.
Eysselein, VE; Greten, H; Isenberg, JI; Koss, MA; Lenz, HJ; Struck, T; Walsh, JH, 1987
)
0.27
" The cimetidine dose-response curves and the calculated ED50 values were similar in the different experimental situations."( Effects of cimetidine, atropine and pirenzepine on basal and stimulated gastric acid secretion in the rat.
Ekelund, M; Håkanson, R; Vallgren, S, 1987
)
0.27
" We determined the dose-response relationships of pentagastrin for gastric and pancreatic secretion."( Additive interaction of pentagastrin and secretin on pancreatic growth in rats.
Bussjaeger, LJ; Morisset, J; Solomon, TE; Wood, JG, 1987
)
0.27
" dosing the effect of the compound on pentagastrin-stimulated AS and on mucoproteins and bicarbonate content in the gastric juice was measured."( Effects of FCE20700, a new PGE2 derivative, on gastric acid secretion and cytoprotective processes in man.
Barbieri, C; Caldara, R; Cantù, A; Carbone, M; Dubini, A; Ferrari, C; Guslandi, M; Masci, E, 1987
)
0.27
" Dose-response studies were performed using intravenous histamine or tetragastrin."( Stimulation of gastric acid secretion in the rhesus monkey.
Harmon, JW; Trout, HH; Zinner, M, 1985
)
0.27
" Analysis of the dose-response curves for the enzyme-activating effect of pentagastrin and cholecystokinin-octapeptide indicated that the D50 values for these two stimulants were not altered by shunting but that the maximal enzyme activation was greatly elevated."( Effects of portacaval shunt on the rat stomach.
Ekelund, M; Håkanson, R; Holmin, T; Oscarson, J; Rehfeld, JF; Sundler, F; Westrin, P, 1985
)
0.27
" Conscious gastric-cannulated rats were given [(3)H]histidine and aminoguanidine by dosage procedures intended to build up fast-turnover and slow-turnover pools of tissue [(3)H]histamine."( The release of histamine during gastric acid secretion in conscious rats.
el-Munshid, HA; Lake, HJ, 1974
)
0.25
" Dose-response experiments with five doses of pentagastrin or histamine (single-dose studies) and two doses of beta 2-agonist suggested a change after vagotomy in the mechanisms of inhibition of gastric acid secretion: for pentagastrin, from a non-competitive type to an uncompetitive type, and for histamine, from a competitive type to a non-significant inhibition."( Effect of beta 2-sympathomimetic on pentagastrin- and histamine-stimulated gastric acid secretion in vagotomized gastric fistula dogs.
Andersen, D; Gottrup, F; Ornsholt, J, 1980
)
0.26
"The H2-receptor antagonists ranitidine and cimetidine were tested against gastric secretory dose-response curves to histamine, pentagastrin and bethanechol in the Heidenhain-pouch dog."( The effect of ranitidine on gastric acid secretory response curves to histamine, pentagastrin or bethanechol in the dog with a Heidenhain pouch.
Bunce, KT; Daly, MJ; Humphray, JM; Stables, R, 1981
)
0.26
" Dose-response experiments with five logarithmically increased doses of pentagastrin and one dose of isoprenaline showed unchanged calculated maximum response and an increase in half-maximum acid response."( Effect of isoprenaline on pentagastrin-stimulated gastric acid secretion in dogs with gastric fistula.
Andersen, D; Bech, K; Gottrup, F; Hovendal, CP, 1981
)
0.26
" Sucralfate was administered orally in dosage schedules of 50 mg, 100 mg or 200 mg before and at 3 and 6 hr after commencing a 24 hr continuous infusion of pentagastrin and bethanechol."( Prevention of experimental duodenal ulcer in the rat by sucralfate.
Ackert, G; Anfang, C; Bank, S; Kranz, V; Smolow, CR, 1983
)
0.27
" Mean inhibitions of MAO during the 4th h after dosing of SK&F 93479 were significant at all dose levels, and a significant effect could still be seen during the 26th h for the two oral doses."( Repeated pentagastrin-stimulated gastric acid secretory tests carried out in the evaluation of the pharmacodynamics of a new histamine H2-receptor antagonist, SK&F 93479.
Bodemar, G; Jönsson, KA; Norlander, B; Walan, A, 1984
)
0.27
" Similar dose-response curves were found for non-vagotomized dogs with high beta 2-adrenergic tone and dogs with low vagal tone (vagotomy) after pentagastrin and histamine stimulated acid secretion."( Adrenergic receptors and gastric secretion in dogs. Is a "tonic balance" relationship between vagal and beta 2-adrenergic activity a possibility?
Andersen, D; Bech, K; Gottrup, F; Hovendal, C, 1984
)
0.27
" Dose-response experiments with bethanechol and dopamine showed inhibition of a non-competitive type."( Dopaminergic and beta-adrenergic effects on gastric antral motility.
Andersen, D; Bech, K; Gottrup, F; Hovendal, CP, 1984
)
0.27
" The dose-response kinetics with seven doses of pentagastrin with and without somatostatin showed inhibition of a competitive type for gastric acid secretion and of a non-competitive type for antral motility with regard to amplitude."( Effect of somatostatin on pentagastrin-stimulated gastric acid secretion and gastric antral motility in dogs with gastric fistula.
Andersen, D; Bech, K, 1984
)
0.27
"To investigate the mechanism of intracellular transmission of three representative stimuli for gastric acid secretion, the dose-response relations of cyclic nucleotides accompanied by acid secretion stimulated by histamine, pentagastrin and bethanechol were comparatively studied using an in vitro preparation of guinea pig gastric mucosa surviving with a constant potential difference and acid secretion sensitive to amytal."( Cyclic nucleotide response to acid-secreting stimuli in guinea pig gastric mucosa in vitro.
Matsumoto, H; Miyoshi, A; Ohe, K; Shirakawa, T, 1981
)
0.26
" The 10 responders were studied both after a single 150 mg dose (SD) and after multiple dosing (MD) with ranitidine 150 mg twice daily for 4 weeks."( The pharmacokinetics of ranitidine in patients with chronic duodenal ulceration: a comparison of responders and non-responders.
Folb, PI; Marks, IN; McFadyen, ML; Miller, R; Moshal, MG, 1983
)
0.27
" Dose-response studies were carried out on different days with increasing doses of doxepin on a constant background stimulation with pentagastrin and with increasing doses of pentagastrin in combination with a constant dose of doxepin."( Effect of doxepin on gastric secretion in man.
Andersen, OK; Burhol, P; Giercksky, KE; Oyen, D, 1984
)
0.27
"By means of pull--through perfusion manometry and by means of continuous intraoesophageal pH measurements comparative study on a uniform group of patients (n = 34) has shown that pentagastrin (Acignost R) at a dosage of 6 mg/kg body weight administered subcutaneously increases mean sphincter pressure and total reflux duration."( [Effect of pentagastrin on the closing pressure of the inferior esophageal sphincter and gastroesophageal reflux].
Linar, EIu; Pfliuke, F, 1983
)
0.27
" These data suggest that in the rat, at least pharmacological dosage of CT modulates the production and/or secretion of glandular CT itself."( Inhibition of calcitonin secretion by exogenous calcitonin in the rat.
Avioli, LV; Birge, SJ; Fausto, A; Morimoto, S, 1984
)
0.27
" Dose-response studies to intravenous pentagastrin showed that the chagasic patients exhibited a lower sensitivity to the stimulant than did the controls, as demonstrated by shifting of the dose-response curve to the right and higher individual values of the dose for half maximal contraction (D50)."( Lower oesophageal sphincter response to pentagastrin in chagasic patients with megaoesophagus and megacolon.
Dantas, RO; Godoy, RA; Meneghelli, UG; Oliveira, RB; Padovan, W; Troncon, LE, 1980
)
0.26
" After intragastric instillation, dose-response curves of H-CT and S-CT were in a similar range when the dose was referred to the molarity of CT; however, related to the biological activity of CT (MRC units), S-CT was about 10--15 times less effective than H-CT."( Inhibition of human gastric secretion by intragastrically administered calcitonin.
Goebell, H; Hirche, H; Hotz, J; Minne, H; Ziegler, R, 1980
)
0.26
" When the study was repeated during infusion of glucagon, the dose-response curve was shifted to the right."( Interaction of glucagon and pentagastrin on pepsin secretion in healthy subjects.
Christiansen, J; Holst, JJ; Molin, J, 1982
)
0.26
" Dose-response curves for pentagastrin were determined for acid output and mucosal blood flow, which was measured with the Neutral Red technique."( Difference in kinetics between the distal and proximal parts of the canine parietal cell mass in response to pentagastrin.
Larsson, JO, 1982
)
0.26
" Consequently, ED50 values in normal subjects and DU patients showed a large scatter and were not significantly different, although the potency ratio calculated from the linear parts of the respective dose-response curves was significantly different (2."( Sensitivity of the parietal cell to pentagastrin in health and duodenal ulcer disease: a reappraisal.
Bangerter, U; Galeazzi, R; Häcki, WH; Halter, F; Rotzer, A; Schlup, M; Varga, L; Wyder, S, 1982
)
0.26
" By the fifth wk, there was an apparent dose-response effect in which the lower two doses produced increased LES pressure and the larger two doses produced decreased LES pressures."( Ontogenic studies of gastrointestinal function. II. Lower esophageal sphincter maturation in neonatal beagle puppies.
Morriss, FH; Spedale, SB; Weisbrodt, NW, 1982
)
0.26
"The dose-response (DR) curves for acid output to intravenous pentagastrin were determined by two techniques in conscious rats with chronic gastric fistula."( Comparison of the dose-response curves for acid output to pentagastrin determined by two techniques in chronic gastric fistula rats.
Emås, S; Nylander, G; Wallin, B, 1981
)
0.26
" Linear transformation of the dose-response curve indicated mixed inhibition."( Importance of the kidneys for gastrin elimination and gastric function.
El Munshid, HA; Håkanson, R; Liedberg, G; Rehfeld, JF; Sundler, F, 1980
)
0.26
" After recovery, dose-response curves were obtained with different doses of pentagastrin, and the maximal acid output was determined."( Non-gastrin, intestinal-phase secretion. Experimental confirmation in the dog.
Bombeck, CT; Donahue, PE; Grabner, ET; Grabner, P; Kalahanis, NG; Nyhus, LM, 1980
)
0.26
"In a dose-response study we investigated the effect of low doses of pentagastrin (less than 1000 ng/kg/h) on the output of gastric lipase measured by a kinetic assay and an enzyme-linked immunosorbent assay (ELISA)."( Low doses of pentagastrin stimulate gastric lipase secretion in man.
Nørregaard, P; Olsen, O; Sternby, B; Worning, H; Wøjdemann, M, 1995
)
0.29
" Individual histamine dose-response curves were shifted to the right by increasing ranitidine and cimetidine concentrations (0."( Secretagogue-induced [14C]aminopyrine uptake in isolated equine parietal cells.
Campbell-Thompson, M, 1994
)
0.29
" However, the dose-response curve for pentagastrin in the presence of ranitidine plus IBMX was similar to that obtained in the absence of IBMX."( Gastrin action on aminopyrine accumulation in isolated pig parietal cells requires cAMP.
Cabero, JL; Li, ZQ; Mårdh, S, 1993
)
0.29
"3 mg/kg) which shifted the dose-response curve to the right."( An investigation into the discriminative stimulus and reinforcing properties of the CCKB-receptor antagonist, L-365,260 in rats.
Bentley, G; Bourson, A; Hargreaves, R; Iversen, S; Jackson, A; Rycroft, W; Tattersall, D; Tricklebank, M, 1994
)
0.29
" Next, a controlled-release (CR) dosage form of pranoprofen was tentatively prepared by combining A-, B- and C-granules at the ratio of 3:4:3 (w/w in contents of pranoprofen)."( Gastrointestinal physiology-regulated dogs for bioavailability evaluation of an oral controlled-release dosage form composed of pulsatile release granules.
Kawata, M; Matsuura, Y; Sagara, K; Shibata, M; Yamada, I, 1996
)
0.29
"Twenty-four healthy subjects were dosed with either famotidine 10 mg, ranitidine 75 mg or placebo in a balanced three-period cross-over design."( Early and late effects of low-dose famotidine, ranitidine or placebo on pentagastrin-stimulated gastric acid secretion in man.
Cottrell, J; Grimley, CE; Loft, DE; Mann, SG; Nwokolo, CU; Stauffer, L; West, JM, 1996
)
0.29
" During the late period (7-9 h post-dose), when the subjects were dosed with placebo, mean gastric acid output was 41."( Early and late effects of low-dose famotidine, ranitidine or placebo on pentagastrin-stimulated gastric acid secretion in man.
Cottrell, J; Grimley, CE; Loft, DE; Mann, SG; Nwokolo, CU; Stauffer, L; West, JM, 1996
)
0.29
" infusion of TP-680 in rats caused a parallel rightward shift of the entire dose-response curve for cholecystokinin octapeptide (CCK-8)-stimulated pancreatic exocrine secretion without altering the maximal response (ID50 = 480 nmol/kg)."( Pharmacological profile of a new serine derivative cholecystokinin receptor antagonist TP-680 on pancreatic, biliary and gastric function.
Kanagawa, K; Otsuki, M; Tachibana, I; Yamamoto, Y, 1996
)
0.29
" To further explore the utility of pentagastrin as a challenge agent and to determine whether its effects are dose-related, a dose-response study was conducted in ten healthy volunteers."( Peptides and anxiety: a dose-response evaluation of pentagastrin in healthy volunteers.
Geraci, M; McCann, UD; Slate, SO; Uhde, TW,
)
0.13
" Significant elevations in HR and BP were seen at all doses, without clear dose-response relationships."( Dose response of adrenocorticotropin and cortisol to the CCK-B agonist pentagastrin.
Abelson, JL; Liberzon, I, 1999
)
0.3
" To explore relationships between CCK-B receptor activation, the HPA axis response, and AVP release, a dose-response study using the CCK-B receptor agonist pentagastrin was conducted."( Dose response of arginine vasopressin to the CCK-B agonist pentagastrin.
Abelson, JL; Bichet, DG; Le Mellédo, J, 2001
)
0.31
" The effect of selective concentrations of CCK(1) and CCK(2) receptor antagonists (L-364,718 and JB93182, respectively) was determined on agonist concentration-effect (E/[A]) curves obtained by cumulative dosing with sulphated CCK."( Pharmacological characterization of cholecystokinin receptors mediating contraction of human gallbladder and ascending colon.
Morton, MF; Shankley, NP; Tavares, IA; Welsh, NJ, 2002
)
0.31
" Intravenous pantoprazole inhibited acid output in a dose-response fashion, with maximal inhibition (99."( Proton pump activation in stimulated parietal cells is regulated by gastric acid secretory capacity: a human study.
Bochenek, WJ; Ferron, GM; Metz, DC; Paul, J; Pisegna, JR; Soffer, E; Turner, MB, 2002
)
0.31
"A multitier approach was successful in identifying a solid dosage form that minimizes the pH-dependent absorption of this drug candidate."( Formulation of solid dosage forms to overcome gastric pH interaction of the factor Xa inhibitor, BMS-561389.
Badawy, SI; Gray, DB; Hussain, MA; Schuster, AE; Sun, D; Zhao, F, 2006
)
0.33
"1 mol/l HCl-KCl buffer should be administered orally, 15 min before the dosage form."( Modification of gastric pH in the fasted dog.
Abrahamsson, B; Albery, T; Dressman, J; Polentarutti, B, 2010
)
0.36
" In this way, as for the surgical procedure, total thyroidectomy is recommended in cases of bilateral goiter, while lobectomy can be offered for cases with single nodes with serum dosage of bCT in the strict follow up."( Incidental medullary thyroid microcarcinoma revealed by mild increase of preoperative serum calcitonin levels: therapeutic implications.
Boschin, IM; Colletti, PM; Ide, EC; Pelizzo, MR; Pennelli, G; Rampin, L; Rubello, D; Toniato, A; Torresan, F; Zane, M, 2014
)
0.4
"The ability to extrapolate dosage performance from in vitro to in vivo situations has an important role in early drug development."( Use of the pentagastrin dog model to explore the food effects on formulations in early drug development.
Guo, Z; MacGerorge, D; Ollier, C; Vicat, P; Zane, P, 2014
)
0.4
" In order to control the gastric pH in rats and dogs, appropriate dosing conditions were investigated using pentagastrin and rabeprazole, which stimulate and inhibit gastric acid secretion."( Evaluation of Acid Tolerance of Drugs Using Rats and Dogs Controlled for Gastric Acid Secretion.
Amano, N; Fujioka, Y; Furuta, A; Igari, T; Kosugi, Y; Sano, N; Yamamoto, S, 2015
)
0.42
" In this randomized, open-label, three-way crossover study, the subjects were dosed with esomeprazole 10 mg or 20 mg once a day (q."( Esomeprazole inhibits the pentagastrin-stimulated secretion of gastric acid in healthy Japanese volunteers.
Iijima, K; Koike, T; Maejima, R; Nakagawa, K; Shimosegawa, T, 2015
)
0.42
" These differences should be kept in mind if the dog model is used to assess the in vivo performance of solid oral dosage forms intended for use in humans."( Characterization of the GI transit conditions in Beagle dogs with a telemetric motility capsule.
Blattner, SM; Boeck, G; Bollmann, T; Grimm, M; Koziolek, M; Lotz, R; Schäfer, KJ; Weitschies, W, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
organic molecular entityAny molecular entity that contains carbon.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency17.23250.000714.592883.7951AID1259369; AID1259392
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency19.49710.01237.983543.2770AID1645841
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency30.10650.000214.376460.0339AID720691
cytochrome P450 2D6Homo sapiens (human)Potency34.67130.00108.379861.1304AID1645840
aryl hydrocarbon receptorHomo sapiens (human)Potency26.60320.000723.06741,258.9301AID743085
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cholecystokinin receptor type ARattus norvegicus (Norway rat)IC50 (µMol)0.88750.00000.43624.3000AID52896; AID52912; AID52916; AID53031
Gastrin/cholecystokinin type B receptorHomo sapiens (human)IC50 (µMol)0.00100.00010.36154.0000AID1683252
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gastrin/cholecystokinin type B receptorRattus norvegicus (Norway rat)EC50 (µMol)0.00040.00040.00080.0014AID1683254
Gastrin/cholecystokinin type B receptorHomo sapiens (human)EC50 (µMol)0.00280.00000.00850.0270AID1683253
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (9)

Processvia Protein(s)Taxonomy
gastric acid secretionGastrin/cholecystokinin type B receptorHomo sapiens (human)
cell surface receptor signaling pathwayGastrin/cholecystokinin type B receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayGastrin/cholecystokinin type B receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationGastrin/cholecystokinin type B receptorHomo sapiens (human)
positive regulation of cell population proliferationGastrin/cholecystokinin type B receptorHomo sapiens (human)
cholecystokinin signaling pathwayGastrin/cholecystokinin type B receptorHomo sapiens (human)
pH reductionGastrin/cholecystokinin type B receptorHomo sapiens (human)
digestive tract developmentGastrin/cholecystokinin type B receptorHomo sapiens (human)
gland developmentGastrin/cholecystokinin type B receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
cholecystokinin receptor activityGastrin/cholecystokinin type B receptorHomo sapiens (human)
protein bindingGastrin/cholecystokinin type B receptorHomo sapiens (human)
gastrin receptor activityGastrin/cholecystokinin type B receptorHomo sapiens (human)
peptide hormone bindingGastrin/cholecystokinin type B receptorHomo sapiens (human)
type B gastrin/cholecystokinin receptor bindingGastrin/cholecystokinin type B receptorHomo sapiens (human)
1-phosphatidylinositol-3-kinase regulator activityGastrin/cholecystokinin type B receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
plasma membraneGastrin/cholecystokinin type B receptorHomo sapiens (human)
intracellular membrane-bounded organelleGastrin/cholecystokinin type B receptorHomo sapiens (human)
plasma membraneGastrin/cholecystokinin type B receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (57)

Assay IDTitleYearJournalArticle
AID1683253Agonist activity at human CCK2R expressed in human A431 cells assessed as intracellular calcium mobilization measured after 24 hrs by Fluo-4AM dye based fluorimetry analysis2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Stabilization Strategies for Linear Minigastrin Analogues: Further Improvements
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID52912Concentration required to inhibit by 50% specific binding of [125I](BH)-CCK-8 to cholecystokinin type A receptor in rat pancreatic acini1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Structure-antigastrin activity relationships of new (R)-4-benzamido-5-oxopentanoic acid derivatives.
AID224402Charecterization of agonist response of ligand in mouse stomach bioassay measured as affinity of L-3652602001Journal of medicinal chemistry, Apr-12, Volume: 44, Issue:8
Nonpeptide cholecystokinin-2 receptor agonists.
AID52896Evaluated for inhibition of cholecystokinin type A receptor by displacing [125I]bolton hunter CCK-8 radioligand in the rat pancreas1992Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14
Rationally designed "dipeptoid" analogues of CCK. Acid mimics of the potent and selective non-peptide CCK-B receptor antagonist CI-988.
AID50512Ratio calculated as IC50 ratio of CCK-A to that of CCK-B1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Rationally designed "dipeptoid" analogues of CCK. alpha-Methyltryptophan derivatives as highly selective and orally active gastrin and CCK-B antagonists with potent anxiolytic properties.
AID51113Inhibition of binding of [125I]Bolton-Hunter labeled CCK-8 to cholecystokinin type B receptor in the mouse cerebral cortex1993Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5
Cholecystokinin dipeptoid antagonists: design, synthesis, and anxiolytic profile of some novel CCK-A and CCK-B selective and "mixed" CCK-A/CCK-B antagonists.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID51292Ratio of IC50 against CCK-B1 and CCK-B(B2) binding1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Structure-antigastrin activity relationships of new (R)-4-benzamido-5-oxopentanoic acid derivatives.
AID1683254Agonist activity at rat CCK2R expressed in rat AR42J cells assessed as intracellular calcium mobilization measured after 24 hrs by Fluo-4AM dye based fluorimetry analysis2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Stabilization Strategies for Linear Minigastrin Analogues: Further Improvements
AID51443Inhibition of the specific binding of [125I](BH)-CCK-8 to Cholecystokinin type B receptor in rat brain cortex1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Structure-antigastrin activity relationships of new (R)-4-benzamido-5-oxopentanoic acid derivatives.
AID51288Concentration required to inhibit by 50% the specific binding of [3H]pentagastrin to cholecystokinin type B receptor in rabbit gastric gland1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Structure-antigastrin activity relationships of new (R)-4-benzamido-5-oxopentanoic acid derivatives.
AID51107Evaluated for inhibition of cholecystokinin type B receptor by displacing [125I]-Bolton hunter CCK-8 radioligand in the mouse cerebral cortex1992Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14
Rationally designed "dipeptoid" analogues of CCK. Acid mimics of the potent and selective non-peptide CCK-B receptor antagonist CI-988.
AID224403Charecterization of agonist response of ligand in mouse stomach bioassay2001Journal of medicinal chemistry, Apr-12, Volume: 44, Issue:8
Nonpeptide cholecystokinin-2 receptor agonists.
AID51120Half-maximal inhibition of specific binding of [125I]bolton hunter CCK-8 to mouse cerebral cortex cholecystokinin type B receptor1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Rationally designed "dipeptoid" analogues of CCK. alpha-Methyltryptophan derivatives as highly selective and orally active gastrin and CCK-B antagonists with potent anxiolytic properties.
AID50511Ratio between IC50 CCK-A vs IC50 CCK-B(B2)1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Structure-antigastrin activity relationships of new (R)-4-benzamido-5-oxopentanoic acid derivatives.
AID52916Inhibition of binding of [125I]Bolton-Hunter labeled CCK-8 to cholecystokinin type A receptor in the rat pancreas.1993Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5
Cholecystokinin dipeptoid antagonists: design, synthesis, and anxiolytic profile of some novel CCK-A and CCK-B selective and "mixed" CCK-A/CCK-B antagonists.
AID234374Selectivity ratio is IC50 value of CCK-A receptor to that of CCK-B receptor1993Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5
Cholecystokinin dipeptoid antagonists: design, synthesis, and anxiolytic profile of some novel CCK-A and CCK-B selective and "mixed" CCK-A/CCK-B antagonists.
AID53031Half-maximal inhibition of specific binding of [125I]bolton hunter CCK-8 to rat pancreas cholecystokinin type A receptor1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Rationally designed "dipeptoid" analogues of CCK. alpha-Methyltryptophan derivatives as highly selective and orally active gastrin and CCK-B antagonists with potent anxiolytic properties.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1683252Displacement of [125I][3-iodo Tyr12,Leu15]gastrin-I from human CCK2R expressed in human A431 cells measured after 1 hr by gamma counter analysis2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Stabilization Strategies for Linear Minigastrin Analogues: Further Improvements
AID50510Inhibition ratio on CCK-A receptor with respect to CCK-B receptor1992Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14
Rationally designed "dipeptoid" analogues of CCK. Acid mimics of the potent and selective non-peptide CCK-B receptor antagonist CI-988.
AID52407Displacement of [3H]pentagastrin from Cholecystokinin receptor of mouse cerebral cortex1987Journal of medicinal chemistry, Apr, Volume: 30, Issue:4
Synthesis and binding affinities of analogues of cholecystokinin-(30-33) as probes for central nervous system cholecystokinin receptors.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID224404Charecterization of agonist response of ligand in mouse stomach bioassay measured as Slope of schild plot2001Journal of medicinal chemistry, Apr-12, Volume: 44, Issue:8
Nonpeptide cholecystokinin-2 receptor agonists.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (3,433)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902620 (76.32)18.7374
1990's574 (16.72)18.2507
2000's177 (5.16)29.6817
2010's52 (1.51)24.3611
2020's10 (0.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials207 (5.69%)5.53%
Reviews75 (2.06%)6.00%
Case Studies70 (1.92%)4.05%
Observational0 (0.00%)0.25%
Other3,287 (90.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]